By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cypralis 

Babraham Hall
Babraham Research Campus
Cambridge    CB22 3AT  United Kingdom
Phone: 44-0-1277-367-020 Fax: 44-0-1277-367-099


SEARCH JOBS

Cypralis was spun out from Selcia Ltd (Ongar, Essex) in 2013 to exploit its extensive expertise and know-how in targeting peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets involved in many acute and chronic diseases. Cypralis is dedicated to the discovery and development of highly innovative therapeutics for the inhibition of PPIases and expects to build upon its existing intellectual property estate through its own R&D activities and also through risk-sharing collaborations with pharmaceutical companies.

YEAR FOUNDED:

2013

LEADERSHIP:

CEO: Simon Kerr

FOLLOW CYPRALIS:




Key Statistics


Email: contact@cypralis.com
Ownership: Private

Web Site: Cypralis
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->